Abstract
A new endothelin-converting enzyme inhibitor PP-35 including Nα-benzylsuccinyl group and Leu-Trp-OH dipeptide is synthesized. Similarly to phosphoramidon substance PP-35 abolishes elevation of systemic blood pressure and heart rate decrease in normotensive rats in response to bolus injection of big endothelin-1. Hemodynamic responses to endothelin-1 remain unchanged.
Similar content being viewed by others
References
O. A. Gomazkov, V. F. Pozdnev, E. V. Kalinina,et al., Byull. Eksp. Biol. Med.,122, No. 9, 279–281 (1996).
E. V. Kalinina, V. F. Pozdnev, N. V. Komissarova, and O. A. Gomazkov,Biokhimiya,62, No. 3, 247–250 (1997).
K. Barnes, K. Shimada, M. Takahashi,et al., J. Cell. Sci.,109, 919–928 (1996).
R. Bihovsky, B. Levinson, R. Loewi,et al., J. Med. Chem.,38, 2119–2129 (1995).
R. Corder and J. Vane,Biochem. Pharmacol.,49, 375–380 (1995).
P. Deprez, J. Guillaume, J. Dumas, and J.-P., Vevert,Bioorg. Med. Chem. Lett.,6, 2317–2322 (1996).
P. Dispaquale, L. Valdes, V. Albano,et al., J. Cardiovasc. Pharmacol.,29, 202–208 (1997).
S. Galatiusjensen, H. Wroblewski, C. Emmeluth,et al., Cardiovasc. Res.,32, 1148–1154 (1996).
G. Gray and D. Webb,Pharmacol. Ther. 72, 109–148 (1996).
P. Kukkola, N. Bilci, W. Kozak,et al., Bioorg. Med. Chem. Lett.,6, 619–624 (1996).
A. Morita, M. Nomizu, M. Okitsu,et al., FEBS Lett.,353, 84–88 (1994).
A. Patil, A. Freyer, D. Eggleston,et al., J. Nat. Prod.,60, 306–308 (1997).
R. Rhoten, Y. Comair, D. Shedid,et al., J. Neurosurg.,86, 101–108 (1997).
Y. Tsurumi, H. Uede, K. Hayashi,et al., J. Antibiot. (Tokyo), 48, 1066–1075 (1995).
A. Turner and L. Murphy,Biochem. Pharmacol.,51, 91–102 (1996).
M. Yangisawa, H. Kurihara, S. Kimura,et al., Nature,332, 411–415 (1988).
Author information
Authors and Affiliations
Additional information
Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 126, No. 11, pp. 526–529, November, 1998
Rights and permissions
About this article
Cite this article
Pozdnev, V.F., Gomazkov, O.A., Davydova, M.P. et al. Synthesis and hemodynamic effects of a new endothelin-converting enzyme inhibitor. Bull Exp Biol Med 126, 1110–1112 (1998). https://doi.org/10.1007/BF02447247
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02447247